A brand new examine has sparked debate on the prevalence of withdrawal signs when sufferers cease taking antidepressants, in addition to on the severity of these signs.
AYESHA RASCOE, HOST:
About 11% of adults within the U.S. take antidepressants. And lately, extra sufferers have come ahead to speak about how they’ve struggled with signs of withdrawal after they cease taking the medicine. A brand new examine launched final week renewed debate concerning the scale of this downside with antidepressants and the gaps in what we all know. NPR’s Will Stone has been protecting this subject and joins me. Hello, Will.
WILL STONE, BYLINE: Hey there.
RASCOE: Let’s begin with this new analysis. Why did this examine get lots of consideration?
STONE: Nicely, it is wading into a really controversial subject in psychiatry, particularly within the U.Okay. There’s growing concern about how usually individuals battle with signs after they cease antidepressants, mostly prescribed being SSRIs.
So this examine was simply printed in a high medical journal, JAMA Psychiatry. It analyzed present knowledge from about 50 medical trials that quantities to greater than 17,000 sufferers and located an individual who goes off these drugs experiences, on common, another symptom in comparison with those that cease a placebo or proceed with the remedy throughout the first week.
Principally, the authors conclude it is beneath the brink for what’s thought of clinically vital. Dr. Sameer Jauhar led the examine and is a psychiatrist at Imperial Faculty London.
SAMEER JAUHAR: It is discovering that there are medical signs of withdrawal that you do not see with placebo – specifically nausea, vertigo, dizziness – that maps on to the pharmacological foundation for the medication and that these exist. They’re simply not quite common.
STONE: One factor to notice is that this work was probably not designed to quantify total simply how usually these signs occur.
RASCOE: So do now we have a solution to that query? How usually do individuals have withdrawal signs?
STONE: Nicely, the quick reply isn’t actually. There’s not good knowledge right here. There was one other evaluation of the present proof final yr that discovered 15% of sufferers had withdrawal signs if you factored in placebo, and most of those weren’t extreme. Now, the elemental downside right here is there actually aren’t high-quality trials which have particularly targeted on measuring withdrawal signs, and the info on the market tends to be from individuals who have been on the medication for a brief time period.
RASCOE: And what is the matter with specializing in individuals on it for a brief time period?
STONE: Nicely, the primary critique from researchers and sufferers is that the most important issues are available when persons are on these medication for years. One outstanding voice on this debate is John Learn. He is a medical psychologist on the College of East London. He is very crucial of this new examine and its conclusions.
JOHN READ: They’re saying it isn’t a clinically vital phenomenon. And that is not one thing you possibly can compromise on. That’s fully inaccurate, outrageous and deceptive to the general public.
STONE: Now, the backstory right here is Learn labored on one other overview examine again in 2019. They discovered about half of individuals have withdrawal signs and that many have been extreme. They didn’t simply embody high-quality randomized managed trials, although. They factored in affected person surveys. And the pushback there, from Dr. Jauhar and others, is that this led to an overinflated and alarmist image.
RASCOE: It actually seems like there’s lots of uncertainty right here. How are others in psychiatry reacting?
STONE: Yeah, with out some new trials, this is not going to be resolved in any definitive manner. I spoke to Awais Aftab about this. He is a psychiatrist at Case Western Reserve College who was not concerned in any of those research. He thinks the methodology within the JAMA examine was strong, however he worries the authors underplayed the extent of the issue.
AWAIS AFTAB: The hazard there’s that the career and the general public can take the incorrect message from this paper and say, oh, withdrawal isn’t an enormous subject. It isn’t an enormous deal. That may completely be the incorrect conclusion. The examine opens extra questions than it solutions.
STONE: Aftab says this has change into extremely polarized. On the one hand, psychiatrists are legitimately anxious this might discourage individuals from taking antidepressants, which might be lifesaving. However on the opposite, and NPR simply reported on this, there’s a motion of sufferers who describe debilitating signs after stopping these drugs.
RASCOE: That is NPR’s Will Stone. Thanks a lot for speaking with us in the present day.
STONE: Thanks.
(SOUNDBITE OF GUTS’ “METIS”)
Copyright © 2025 NPR. All rights reserved. Go to our web site phrases of use and permissions pages at www.npr.org for additional info.
Accuracy and availability of NPR transcripts might differ. Transcript textual content could also be revised to right errors or match updates to audio. Audio on npr.org could also be edited after its authentic broadcast or publication. The authoritative document of NPR’s programming is the audio document.
